EICHORCondition: Non Small Cell Lung Cancer · ALK-positive Non-small Cell Lung Cancer (NSCLC) · Sponsor: Nuvalent Inc.
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The Expanded Access Program will provide an alternate mechanism for patients, who lack satisfactory therapeutic alternatives and cannot participate in a neladalkib clinical trial, to access investigational neladalkib.
This description comes directly from the study's public registry record.
Contact for Program Information · 877 768 4303 · MedicineAccess@clinigengroup.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Age ≥18 years. 2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC or other solid tumors with a documented ALK rearrangement or activating ALK mutation. 3. Previously received at least one ALK TKI (for patients with NSCLC) or any prior therapy (for patients with other solid tumors), with no comparable or satisfactory alternative treatment options, in the opinion of the treating physician. 4. Enrollment in a clinical trial of neladalkib is not possible. 5. Adequate organ function and bone marrow reserve. Exclusion Criteria: 1. Prior receipt of neladalkib. 2. Previous surgery, chemotherapy, radiotherapy or other anti-cancer therapy or participation in other studies within timeframe indicated in the protocol. 3. Ongoing anti-cancer therapy.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| University Of California Irvine Medical Center | Orange, California, United States | Available |
| University of Colorado Anschutz School of Medicine | Aurora, Colorado, United States | Available |
| University of Chicago Medical Center | Chicago, Illinois, United States | Available |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Available |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Available |
| Henry Ford Cancer Institute | Detroit, Michigan, United States | Available |
| Washington University in St. Louis | St Louis, Missouri, United States | Available |
| NYU Langone Health | New York, New York, United States | Available |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Available |
| Duke University | Durham, North Carolina, United States | Available |
| The Ohio State University | Columbus, Ohio, United States | Available |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Available |
+ 35 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06834074